Assessing Islet Alpha Cell Function in Type 2 Diabetes Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the function of islet alpha cells in newly diagnosed type 2 diabetes patients by measuring various hormone levels before and after a 3-month treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will undergo tests to assess their glucose, insulin, C-peptide, and glucagon levels during fasting, postprandial periods, and during an Oral Glucose Tolerance Test (OGTT). The goal is to determine if GLP-1RA treatment improves islet alpha cell function in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing to participate voluntarily and able to sign the Informed Consent Form before the trial;
* Newly diagnosed patients with type 2 diabetes, aged 18 years or older, meeting the WHO 1999 diagnostic criteria;
* Subjects who are capable and willing to maintain a regular diet and exercise regimen.

Exclusion Criteria:

* Patients who are allergic to GLP-1RA or have a BMI less than 24 kg/m\^2;
* History of using blood sugar-lowering medications;
* Estimated glomerular filtration rate (eGFR) less than 30 ml/(min\*1.73 m\^2);
* History of drug abuse or alcohol dependence within the past 5 years;
* Patients with poor compliance and irregular diet and exercise;
* History of diagnosed pancreatitis, pancreatic tumor, medullary thyroid carcinoma, or diabetic retinopathy stage IV or higher;
* Patients who have used systemic glucocorticoid therapy within the past 3 months;
* Presence of infection or stress within the past four weeks;
* Any other significant condition or comorbidity judged by the researcher, such as severe cardiopulmonary disease, endocrine disorders, neurological disorders, tumors, other pancreatic diseases, mental illness, history of alcohol or drug abuse.

Where it's running

• Nanjing First Hostital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Jianhua Ma, professor
• Email: majianhua196503@126.com
• Phone: 18951670116

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Acupuncture plus vitamin B12 for diabetic heart nerve damage

  This study tests whether adding acupuncture to standard care and vitamin B12 can help adults with type 2 diabetes who have damaged the nerves that control the heart.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07907536

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes

  This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.

  Recruiting at 2 sites Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Mexico City, Mexico City and 1 other locations · NCT07835360

• Single-dose PK study of HRS-4729 in adults with and without kidney impairment

  This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07807059

• Once-daily ASC30 to See if it helps adults with obesity or overweight and Type 2 diabetes

  This study tests three daily doses of ASC30 against placebo in adults who are overweight or obese and have Type 2 diabetes to see if it helps with weight loss and safety over time.

  Recruiting at 6 sites Phase 3 Ascletis Pharma Inc · Birmingham, Alabama and 134 other locations · NCT07743450

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.